{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:37:10Z","timestamp":1789911430596,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70111764"],"award-info":[{"award-number":["70111764"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Faculty of Medicine, University of Freiburg","award":["3091101336"],"award-info":[{"award-number":["3091101336"]}]},{"name":"Deutsches Konsortium f\u00fcr Transnationale Krebsforschung","award":["L661"],"award-info":[{"award-number":["L661"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5045-7","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T08:36:28Z","timestamp":1542616588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-8947","authenticated-orcid":false,"given":"Nikolas","family":"von Bubnoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Grishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"R\u00f6thling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Duyster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"issue":"12","key":"5045_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9674","key":"5045_CR2","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550\u201361.","journal-title":"Lancet"},{"issue":"3","key":"5045_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12185-010-0516-x","volume":"91","author":"C Onishi","year":"2010","unstructured":"Onishi C, et al. A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol. 2010;91(3):464\u201370.","journal-title":"Int J Hematol"},{"key":"5045_CR4","doi-asserted-by":"crossref","unstructured":"Xhaard A, et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation Anticytokine treatment. Biol Blood Marrow Transplant. 2011.","DOI":"10.1016\/j.bbmt.2011.06.012"},{"issue":"3","key":"5045_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1053\/bbmt.2002.v8.pm11939605","volume":"8","author":"S Arai","year":"2002","unstructured":"Arai S, et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant. 2002;8(3):155\u201360.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5045_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-3083.2005.01595.x","volume":"61","author":"M Jaksch","year":"2005","unstructured":"Jaksch M, Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 2005;61(5):398\u2013409.","journal-title":"Scand J Immunol"},{"issue":"4","key":"5045_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.beha.2008.07.003","volume":"21","author":"JL Ferrara","year":"2008","unstructured":"Ferrara JL. Advances in the clinical management of GVHD. Best Pract Res Clin Haematol. 2008;21(4):677\u201382.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"22","key":"5045_CR8","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"issue":"1","key":"5045_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bmt.2009.328","volume":"45","author":"S Paczesny","year":"2010","unstructured":"Paczesny S, et al. New perspectives on the biology of acute GVHD. Bone Marrow Transplant. 2010;45(1):1\u201311.","journal-title":"Bone Marrow Transplant"},{"key":"5045_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.20112408","volume":"209","author":"RR Jenq","year":"2012","unstructured":"Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012;209:903\u201311.","journal-title":"J Exp Med"},{"issue":"6","key":"5045_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nm.3517","volume":"20","author":"Lukas Schwab","year":"2014","unstructured":"Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Friederike D, Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Sch\u00f6nle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, H\u00e4cker H, Hildebrandt GC, H\u00e4cker G, Zeiser R. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage. Nat Med. 2014. \n                    https:\/\/doi.org\/10.1038\/nm.3517\n                    \n                  .","journal-title":"Nature Medicine"},{"key":"5045_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/eji.201344195","volume":"44","author":"S Kalyan","year":"2014","unstructured":"Kalyan S, Kabelitz D. When neutrophils meet T cells: beginnings of a tumultuous relationship with underappreciated potential. Eur J Immunol. 2014;44:627\u201333.","journal-title":"Eur J Immunol"},{"issue":"2","key":"5045_CR13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V90.2.597","volume":"90","author":"K Shimoda","year":"1997","unstructured":"Shimoda K, et al. Jak1 plays an essential role for receptor phosphorylation and stat activation in response to granulocyte colony-stimulating factor. Blood. 1997;90(2):597\u2013604.","journal-title":"Blood"},{"issue":"8","key":"5045_CR14","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1073\/pnas.91.8.2985","volume":"91","author":"SE Nicholson","year":"1994","unstructured":"Nicholson SE, et al. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. Proc Natl Acad Sci U S A. 1994;91(8):2985\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"5045_CR15","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"5045_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"24","key":"5045_CR17","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832\u201342.","journal-title":"Blood"},{"issue":"1","key":"5045_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","volume":"108","author":"R. Zeiser","year":"2006","unstructured":"Zeiser, R., et al., Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood, 2006. 108(1): p. 390\u20139.","journal-title":"Blood"},{"issue":"10","key":"5045_CR19","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062\u20138.","journal-title":"Leukemia"},{"key":"5045_CR20","unstructured":"Zeiser, R., et al., Long-term follow-up of patients with corticosteroid-refractory graft-versus-host disease treated with ruxolitinib. Blood (ASH Annual Meeting Abstracts), 2016. 128(22): p. abstract 4561."},{"key":"5045_CR21","doi-asserted-by":"crossref","unstructured":"Schroeder, M.A., et al. A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD). In 2016 ASH Annual Meeting. 2016. San Diego, CA.","DOI":"10.1182\/blood.V128.22.390.390"},{"key":"5045_CR22","volume-title":"Graft-versus-Host Erkrankung, akut","author":"Onkopedia\/DGHO, Leitlinie","year":"2017","unstructured":"Onkopedia\/DGHO, Leitlinie: Graft-versus-Host Erkrankung, akut. 2017."},{"issue":"1","key":"5045_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"5045_CR24","unstructured":"Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: European Organisation for Research and Treatment of Cancer; 2001."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5045-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:13:05Z","timestamp":1574104385000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5045-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5045"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5045-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"11 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol has been approved by the German Federal Institute for Drugs and Medicine Devices and by the leading independent Ethics Committee of the University of Freiburg (EK 290\/16). The study will be conducted in accordance with the ethical principles of the Declaration of Helsinki, the ICH-GCP Guidelines, the EU Clinical Trial Directive (2001\/20\/EG) and applicable regulatory requirements. Patient\u2019s written consent to participate in this clinical trial is obtained prior to any study-specific procedures. The RIG-study has been registered in the  registry (NCT02396628) and the Deutsches Register Klinische Studien (DRKS00007939).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1132"}}